Quantification of Radiation Injury on Neutropenia and the Link between Absolute Neutrophil Count Time Course and Overall Survival in Nonhuman Primates Treated with G-CSF.


Journal

Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521

Informations de publication

Date de publication:
21 May 2020
Historique:
received: 10 10 2019
accepted: 02 05 2020
entrez: 23 5 2020
pubmed: 23 5 2020
medline: 16 3 2021
Statut: epublish

Résumé

To model absolute neutrophil count (ANC) suppression in response to acute radiation (AR) exposure and evaluate ANC time course as a predictor of overall survival (OS) in response to AR exposure with or without treatment with granulocyte colony-stimulating factor in nonhuman primates. Source data were obtained from two pivotal studies conducted in rhesus macaques exposed to 750 cGy of whole body irradiation on day 0 that received either placebo, daily filgrastim, or pegfilgrastim (days 1 and 8 after irradiation). Animals were observed for 60 days with ANC measured every 1 to 2 days. The population model of ANC response to AR and the link between observed ANC time course and OS consisted of three submodels characterizing injury due to radiation, granulopoiesis, and a time-to-event model of OS. The ANC response model accurately described the effects of AR exposure on the duration of neutropenia. ANC was a valid surrogate for survival because it explained 76% (95% CI, 41%-97%) and 73.2% (95% CI, 38.7%-99.9%) of the treatment effect for filgrastim and pegfilgrastim, respectively. The current model linking radiation injury to neutropenia and ANC time course to OS can be used as a basis for translating these effects to humans.

Identifiants

pubmed: 32440783
doi: 10.1007/s11095-020-02839-3
pii: 10.1007/s11095-020-02839-3
pmc: PMC7242243
doi:

Substances chimiques

pegfilgrastim 3A58010674
Polyethylene Glycols 3WJQ0SDW1A
Filgrastim PVI5M0M1GW

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102

Subventions

Organisme : Amgen Inc.
ID : Not applicable

Références

Radiat Res. 2013 Jan;179(1):89-100
pubmed: 23210705
Drug Metab Rev. 1996 Nov;28(4):625-58
pubmed: 8959393
Clin Transl Sci. 2020 Jul;13(4):807-817
pubmed: 32112517
Ann Oncol. 2003 Jan;14(1):29-35
pubmed: 12488289
J Immunol. 2018 Jun 15;200(12):4059-4067
pubmed: 29728510
Radiat Res. 2015 Jun;183(6):643-55
pubmed: 26035709
Blood. 1992 Jun 1;79(11):2849-54
pubmed: 1375115
Radiat Res. 2012 Nov;178(5):403-13
pubmed: 22991919
Br J Haematol. 1985 Dec;61(4):675-85
pubmed: 4084457
J Clin Oncol. 2010 Mar 10;28(8):1329-36
pubmed: 20142595
J Clin Oncol. 2002 Feb 1;20(3):727-31
pubmed: 11821454
Blood. 2010 Jul 29;116(4):625-7
pubmed: 20410504
Biometrics. 2004 Jun;60(2):451-60
pubmed: 15180671
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
pubmed: 16023764
J Clin Oncol. 2000 Jul;18(13):2522-8
pubmed: 10893282
Blood. 2016 Jun 30;127(26):3431-8
pubmed: 27136946
Br J Clin Pharmacol. 2018 May;84(5):911-925
pubmed: 29318653
Pharm Res. 1998 May;15(5):690-7
pubmed: 9619776
J Pharmacokinet Pharmacodyn. 2007 Feb;34(1):57-85
pubmed: 17051439
BMC Med. 2011 Nov 25;9:126
pubmed: 22114866

Auteurs

John Harrold (J)

Department of Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.
Seattle Genetics, Bothell Washington, Massachusetts, USA.

Per Olsson Gisleskog (PO)

SGS Exprimo NV, Mechelen, Belgium.
POG Pharmacometrics, Hampshire, UK.

Isabelle Delor (I)

SGS Exprimo NV, Mechelen, Belgium.

Philippe Jacqmin (P)

SGS Exprimo NV, Mechelen, Belgium.

Juan Jose Perez-Ruixo (JJ)

Department of Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.
Janssen Research & Development, Valencia, Spain.

Adimoolam Narayanan (A)

Department of Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.

Sameer Doshi (S)

Department of Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.

Andrew Chow (A)

Department of Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.
Rigel Pharmaceuticals Inc., South San Francisco, California, USA.

Bing-Bing Yang (BB)

Department of Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.

Murad Melhem (M)

Department of Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA. murad_melhem@vrtx.com.
Vertex Pharmaceuticals, Boston, Massachusetts, USA. murad_melhem@vrtx.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH